Securities Investigation – Fulcrum Therapeutics Stock – FULC
Investors of Fulcrum Therapeutics Stock Encouraged to Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Fulcrum Therapeutics, Inc. (“Fulcrum” or “Fulcrum Therapeutics”) (NASDAQ: FULC).
On February 24, 2023, shares of Fulcrum Therapeutics stock closed down more than 56%, after Fulcrum ” . . . announced that on February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease. The [FDA] indicated that it would provide a formal Clinical Hold Letter to the company within 30 days.”
Fulcrum Therapeutics also reported that “[t]he clinical hold was initiated by the [FDA] due to previously reported preclinical data. Fulcrum will suspend dosing in the Phase 1b trial of FTX-6058 and intends to work diligently with the [FDA] to resolve the hold as soon as possible.”
INVESTORS OF FULCRUM THERAPEUTICS STOCK WHO HAVE SUFFERED LOSSES ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR SECURITIES.
SHAREHOLDERS OF FULCRUM ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO LEARN MORE ABOUT THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
